AR064406A1 - Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente - Google Patents

Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente

Info

Publication number
AR064406A1
AR064406A1 ARP070105681A ARP070105681A AR064406A1 AR 064406 A1 AR064406 A1 AR 064406A1 AR P070105681 A ARP070105681 A AR P070105681A AR P070105681 A ARP070105681 A AR P070105681A AR 064406 A1 AR064406 A1 AR 064406A1
Authority
AR
Argentina
Prior art keywords
formula
alkyl
compound
composite
halogen
Prior art date
Application number
ARP070105681A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39536720&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064406(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR064406A1 publication Critical patent/AR064406A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Epoxy Compounds (AREA)

Abstract

Compuesto calcilítico derivado de (halo-fenilcarboxil)-hidroxietilamina de la formula (1): en la que: X es halogeno; Y es hidrogeno o halogeno; Z es -CO(O)H o -C(O)O-alquilo C1-5; R2 es alquilo C1-5; R3 es fenilo, tienilo, naftilo o dihidroindenilo, donde los restos tienilo y fenilo están opcionalmente sustituidos, independientemente, una o dos veces, con halogeno, alquilo C1-5, alcoxi C1-5 o alquiltio C1-5; y A es un enlace covalente o alquilo C1-5; o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende y su uso para preparar un medicamento util para antagonizar un receptor de calcio, para tratar una enfermedad o trastorno que comprende una homeostasis osea o mineral anormal como ser osteosarcoma, enfermedad periodontal, curacion de fracturas, osteoartritis, artritis reumatoide, enfermedad de Paget, hipoparatiroidismo, hipercalcemia humoral asociada con malignidad y curacion de fracturas, osteoporosis, osteoporosis o para aumentar los niveles paratiroideos séricos. Dicho uso donde el compuesto de la formula (1) se co-administra con un agente contra la resorcion. Método para sintetizar dicho compuesto y compuesto intermedio correspondiente. Reivindicacion 48: Un método para sintetizar un compuesto de acuerdo con la reivindicacion 1, caracterizado porque comprende las etapas de: (a) tosilacion selectiva de un diol de acuerdo con la formula (2), en la que R8 es alquilo C1-5, y X Y y R2 son como se han definido para la formula (1) en la reivindicacion 1; para producir un tosilato de acuerdo con la formula (3), (b) reaccion del tosilato en presencia de una base para proporcionar un epoxido de acuerdo con la formula (4), y (c) apertura del epoxido con una amina primaria para proporcionar un amino alcohol de acuerdo con la formula (5). Reivindicacion 50: Un intermedio para el método de las reivindicaciones 47 a 49, caracterizado porque se selecciona entre el grupo que consiste en la formula (2), (3) y (4), en las que R8 es alquilo C1-5 y X, Y y R2 son como se han definido en la formula (1) en la reivindicacion 1.
ARP070105681A 2006-12-18 2007-12-18 Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente AR064406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87043206P 2006-12-18 2006-12-18

Publications (1)

Publication Number Publication Date
AR064406A1 true AR064406A1 (es) 2009-04-01

Family

ID=39536720

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105681A AR064406A1 (es) 2006-12-18 2007-12-18 Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente

Country Status (8)

Country Link
US (1) US7902394B2 (es)
EP (1) EP2120898A4 (es)
JP (1) JP2010513564A (es)
AR (1) AR064406A1 (es)
CL (1) CL2007003688A1 (es)
TW (1) TW200845956A (es)
UY (1) UY30801A1 (es)
WO (1) WO2008077009A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5025795B2 (ja) 2008-06-05 2012-09-12 旭化成ファーマ株式会社 スルホンアミド化合物及びその用途
GEP20146104B (en) 2009-11-02 2014-05-27 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2013152476A1 (en) * 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2015101916A1 (en) * 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
CN105085278A (zh) * 2015-08-07 2015-11-25 常州大学 一种2-甲基-1-取代苯基-2-丙胺类化合物的制备方法
CN106117045A (zh) * 2016-06-22 2016-11-16 北京阳光诺和药物研究有限公司 一种苯基丁酸的纯化方法
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112073A4 (en) 1998-08-12 2002-10-25 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
AR042132A1 (es) * 2002-11-26 2005-06-08 Smithkline Beecham Corp Compuesto de 2- hidroxi -3-(2- aril - 1, 1 - dimetiletilamino) propoxifenilo, composicion farmaceutica que lo comprende y uso del mismo para prepararla
DE102004021779A1 (de) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2010513564A (ja) 2010-04-30
CL2007003688A1 (es) 2008-06-27
UY30801A1 (es) 2008-07-03
EP2120898A4 (en) 2011-08-03
WO2008077009A1 (en) 2008-06-26
TW200845956A (en) 2008-12-01
EP2120898A1 (en) 2009-11-25
US20100029782A1 (en) 2010-02-04
US7902394B2 (en) 2011-03-08

Similar Documents

Publication Publication Date Title
AR064406A1 (es) Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente
UY30620A1 (es) Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio
UY29962A1 (es) Compuestos calciliticos
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
BRPI0508622B8 (pt) compostos de bifenil úteis como antagonistas do receptor muscarínico, composição farmacêutica, processo, medicamento e uso do composto.
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
DOP2010000103A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b
UY27154A1 (es) Pirimidinas inhibidoras de metaloproteinasa de matriz
BRPI0907844B8 (pt) compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
UY28482A1 (es) Nuevos compuestos
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
BRPI0410117A (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
TN2010000136A1 (en) Composition comprising sphingosine 1 phosphate (s1p) receptor modulators
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
SE0200920D0 (sv) Novel compounds
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
GT200500119A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
BR122013028005B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos
BRPI0817060A2 (pt) composto, processo para a preparação destes compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são modulados por agonistas receptores de hormônio da tireóide e usos destes compostos
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
TW200616995A (en) Novel compounds
BRPI0511722A (pt) 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina
BRPI0705106A (pt) composições de toner
EA200700130A1 (ru) Композиции, содержащие стронций и витамин d, и их применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure